Methamphetamine Use and Schizophrenia: A Population-Based Cohort Study in California
The DOI matches its Crossref record; 30 of the 30 references it cites were found in a registry or an index.
Abstract
OBJECTIVE: Clinical investigators in Japan have long suggested that exposure to methamphetamine might cause a persistent schizophrenia-like psychosis. This possibility is discounted in the Western literature. To investigate the relationship between drug use and later schizophrenia, the authors conducted a large-scale cohort study of drug users initially free of persistent psychosis. METHOD: A population-based cohort study was conducted using data from California inpatient hospital discharge records from 1990 through 2000. Patients with methamphetamine-related conditions (N=42,412) and those with other drug use disorders (cannabis, cocaine, alcohol, and opioids) were propensity score-matched to individuals with primary appendicitis who served as a population proxy comparison group; the methamphetamine cohort was also matched to the other drug cohorts. Cox modeling was used to estimate differences between matched groups in the rates of subsequent admission with schizophrenia diagnoses. RESULTS: The methamphetamine cohort had a significantly higher risk of schizophrenia than the appendicitis group (hazard ratio=9.37) and the cocaine, opioid, and alcohol groups (hazard ratios ranging from 1.46 to 2.81), but not significantly different from that of the cannabis group. The risk of schizophrenia was higher in all drug cohorts than in the appendicitis group. CONCLUSIONS: Study limitations include difficulty in confirming schizophrenia diagnoses independent of drug intoxication and the possibility of undetected schizophrenia predating drug exposure. The study's findings suggest that individuals with methamphetamine-related disorders have a higher risk of schizophrenia than those with other drug use disorders, with the exception of cannabis use disorders. The elevated risk in methamphetamine users may be explained by shared etiological mechanisms involved in the development of schizophrenia.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“The California Hospital Study reported a large association between hospital admission diagnosis of cannabis use disorder and risk of later hospitalisation for schizophrenia (16) compared to a cohort of subjects who were hospitalised for appendicitis (HR 8.16, 95% CI 5.08, 13.12).”
From Association Between Cannabis and Psychosis: Epidemiologic Evidence (2016) · cites this paper as [16]
In the citing paper
“Studies that assessed hospitalisation for schizophrenia are unlikely to be substantially affected by this bias (12,16).”
From Association Between Cannabis and Psychosis: Epidemiologic Evidence (2016) · cites this paper as [16]
Citations
Cites
Charlson, M. E., Pompei, P., Ales, K. L., & MacKenzie, C. R. (1987) · Journal of Chronic Diseases · doi:10.1016/0021-9681(87)90171-8 · Cited by 49,742
McGrath, J., Saha, S., Welham, J., El Saadi, O., MacCauley, C., & Chant, D. (2004) · BMC Medicine · doi:10.1186/1741-7015-2-13 · Cited by 1,072
Zammit, S., Allebeck, P., Andreasson, S., Lundberg, I., & Lewis, G. (2002) · BMJ · doi:10.1136/bmj.325.7374.1199 · Cited by 871
Self-citationvan Os, J., Rutten, B. P., & Poulton, R. (2008) · Schizophrenia Bulletin · doi:10.1093/schbul/sbn117 · Cited by 713
Stürmer, T., Joshi, M., Glynn, R. J., Avorn, J., Rothman, K. J., & Schneeweiss, S. (2006) · Journal of Clinical Epidemiology · doi:10.1016/j.jclinepi.2005.07.004 · Cited by 670
Austin, P. C. (2007) · The Journal of Thoracic and Cardiovascular Surgery · doi:10.1016/j.jtcvs.2007.07.021 · Cited by 589
Austin, P. C., & Mamdani, M. M. (2006) · Statistics in Medicine · doi:10.1002/sim.2328 · Cited by 560
Shah, B. R., Laupacis, A., Hux, J. E., & Austin, P. C. (2005) · Journal of Clinical Epidemiology · doi:10.1016/j.jclinepi.2004.10.016 · Cited by 493
van Winkel, R., Stefanis, N. C., & Myin-Germeys, I. (2008) · Schizophrenia Bulletin · doi:10.1093/schbul/sbn101 · Cited by 489
Appendectomy: A Contemporary Appraisal
Hale, D. A., Molloy, M., Pearl, R. H., Schutt, D. C., & Jaques, D. P. (1997) · Annals of Surgery · doi:10.1097/00000658-199703000-00003 · Cited by 354
Estimating Treatment Effects Using Observational Data
D’Agostino, R. B. (2007) · JAMA · doi:10.1001/jama.297.3.314 · Cited by 350
Lieberman, J. (1997) · Neuropsychopharmacology · doi:10.1016/s0893-133x(97)00045-6 · Cited by 333
UJIKE, H., & SATO, M. (2004) · Annals of the New York Academy of Sciences · doi:10.1196/annals.1316.035 · Cited by 280
Kashner, T. M. (1998) · Medical Care · doi:10.1097/00005650-199809000-00005 · Cited by 264
Relapse of Paranoid Psychotic State in Methamphetamine Model of Schizophrenia
Sato, M., Numachi, Y., & Hamamura, T. (1992) · Schizophrenia Bulletin · doi:10.1093/schbul/18.1.115 · Cited by 221
Cunningham, J. K., & Liu, L. (2003) · Addiction · doi:10.1046/j.1360-0443.2003.00450.x · Cited by 158
Self-citationIncidence of Parkinson's disease among hospital patients with methamphetamine‐use disorders
Callaghan, R. C., Cunningham, J. K., Sajeev, G., & Kish, S. J. (2010) · Movement Disorders · doi:10.1002/mds.23263 · Cited by 140
Self-citationMINOZZI, S., DAVOLI, M., BARGAGLI, A. M., AMATO, L., VECCHI, S., & PERUCCI, C. A. (2010) · Drug and Alcohol Review · doi:10.1111/j.1465-3362.2009.00132.x · Cited by 78
Rawson, N. S. B., Malcolm, E., & D’Arcy, C. (1997) · Social Psychiatry and Psychiatric Epidemiology · doi:10.1007/bf00788238 · Cited by 73
The Impact of Substance Use on Brain Structure in People at High Risk of Developing Schizophrenia
Welch, K. A., McIntosh, A. M., Job, D. E., Whalley, H. C., Moorhead, T. W., Hall, J., Owens, D. G. C., Lawrie, S. M., & Johnstone, E. C. (2011) · Schizophrenia Bulletin · doi:10.1093/schbul/sbq013 · Cited by 73
Competing Definitions of Schizophrenia: What Can Be Learned From Polydiagnostic Studies?
Jansson, L. B., & Parnas, J. (2007) · Schizophrenia Bulletin · doi:10.1093/schbul/sbl065 · Cited by 73
Grelotti, D. J., Kanayama, G., & Pope, H. G. (2010) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2009.08111695 · Cited by 67
When does amphetamine-induced psychosis become schizophrenia? [clinical conference]
(1996) · American Journal of Psychiatry · doi:10.1176/ajp.153.6.812 · Cited by 67
An increased risk of stroke among young schizophrenia patients
Lin, H., Hsiao, F., Pfeiffer, S., Hwang, Y., & Lee, H. (2008) · Schizophrenia Research · doi:10.1016/j.schres.2007.12.485 · Cited by 66
DSM-V Research Agenda: Substance Abuse/Psychosis Comorbidity
Rounsaville, B. J. (2007) · Schizophrenia Bulletin · doi:10.1093/schbul/sbm054 · Cited by 62
Psychiatric diagnoses as reported to Medicaid and as recorded in patient charts.
Schwartz, A. H., Perlman, B. B., Paris, M., Schmidt, K., & Thornton, J. C. (1980) · American Journal of Public Health · doi:10.2105/ajph.70.4.406 · Cited by 46
Macleod, J., Oakes, R., Oppenkowski, T., Stokes-Lampard, H. J., Copello, A. G., CROME, I. B., Smith, G. D., Egger, M., Hickman, M., & Judd, A. (2004) · Drugs Education Prevention and Policy · doi:10.1080/09687630410001687879 · Cited by 40
An Overview of Methamphetamine-induced Psychotic Syndromes
Zorick, T. S., Rad, D., Rim, C., & TSUANG, J. W. (2008) · Addictive Disorders & Their Treatment · doi:10.1097/adt.0b013e318066d5e0 · Cited by 24
A crosswalk from DSM-III-R to ICD-9-CM
Thompson, J. W., & Pincus, H. A. (1989) · American Journal of Psychiatry · doi:10.1176/ajp.146.10.1315 · Cited by 13
D’Agostino (1998) · doi:10.1002/(sici)1097-0258(19981015)17:19<2265::aid-sim918>3.0.co;2-b
Research works printed but not linked: 5
- Angrist B, 1994, Amphetamine and Its Analogs: Pharmacology, Toxicology, and Abuse, 387
- Zach A, 1990, New Way to Edit: Discharge Data Review
- California Office of Statewide Health Planning and Development, 1995, Editing Criteria Handbook
- Sauerland S, 2004, Cochrane Database Syst Rev, 4, CD001546
- Konuma K, 1994, Amphetamine and Its Analogs: Pharmacology, Toxicology, and Abuse, 415
Cited by
Association Between Cannabis and Psychosis: Epidemiologic Evidence
Gage, S. H., Hickman, M., & Zammit, S. (2016) · Biological Psychiatry · doi:10.1016/j.biopsych.2015.08.001 · Cited by 379
Psychosocial Interventions for People With Both Severe Mental Illness and Substance Misuse
Hunt, G. E., Siegfried, N., Morley, K., Sitharthan, T., & Cleary, M. (2014) · Schizophrenia Bulletin · doi:10.1093/schbul/sbt160 · Cited by 266
Bramness, J. G., Gundersen, Ø. H., Guterstam, J., Rognli, E. B., Konstenius, M., Løberg, E.-M., Medhus, S., Tanum, L., & Franck, J. (2012) · BMC Psychiatry · doi:10.1186/1471-244x-12-221 · Cited by 243
“The similarities between amphetamines’ and cannabis’ risk of being associated with later psychosis is further supported by a newly published record linkage study [107].”
ResultGage, S. H., Jones, H. J., Burgess, S., Bowden, J., Davey Smith, G., Zammit, S., & Munafò, M. R. (2017) · Psychological Medicine · doi:10.1017/s0033291716003172 · Cited by 211
“Some studies (Callaghan et al. 2012; Rossler et al. 2012), although not all (Gage et al. 2014), conducted since this meta-analysis have also found evidence of an association between cannabis use and later psychotic experiences or schizophrenia.”
BackgroundResultMcKetin, R., Leung, J., Stockings, E., Huo, Y., Foulds, J., Lappin, J. M., Cumming, C., Arunogiri, S., Young, J. T., Sara, G., et al. (2019) · EClinicalMedicine · doi:10.1016/j.eclinm.2019.09.014 · Cited by 191
“no amphetamine use disorder) Callaghan (2012) [40] United States 1990–2000 Patients dependent on amphetamines admitted to Californian hospitals as identified through the California inpatient hospital admissions database CO 91 10,815,900 (36,162) 35 22 Schizophrenia diagnosis”
BackgroundInfluential
Metadata
- Authors
- Callaghan, R. C., Cunningham, J. K., Allebeck, P., Arenovich, T., Sajeev, G., Remington, G., Boileau, I., & Kish, S. J.
- Affiliations
- Centre for Addiction and Mental Health (CA)
- From the Centre for Addiction and Mental Health, Toronto; the Dalla Lana School of Public Health, the Departments of Psychiatry and Pharmacology, Faculty of Medicine, and the Institute of Medical Science, University of Toronto, Toronto; the Department of Family and Community Medicine, University of Arizona, Tucson; and the Department of Public Health Sciences, Karolinska Institutet, Stockholm.
- ORCID
- Venue
- American Journal of Psychiatry
- Published
- 2012-04
- Volume
- 169
- Issue
- 4
- Pages
- 389-396
- ISSN
- 0002-953X (ISSN-L)
- 1535-7228
- OpenAlex
- W2055556070
- Cited by
- 150
- References
- 30
- Citations by year
- 2026: 3 · 2025: 4 · 2024: 9 · 2023: 9 · 2022: 6 · 2021: 10 · 2020: 6 · 2019: 8 · 2018: 10 · 2017: 9 · 2016: 13 · 2015: 35 · 2014: 9 · 2013: 13 · 2012: 6
- FWCI
- 6.12
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- American Journal of Psychiatry (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Institute on Drug Abuse (R01DA025096, DA071301, DA025096)
- Topics
- Health Sciences › Medicine › Psychiatry and Mental health › Schizophrenia research and treatment
- Health Sciences › Medicine › Epidemiology › Substance Abuse Treatment and Outcomes
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Toxicology › Forensic Toxicology and Drug Analysis
- Keywords
- methamphetamine use, schizophrenia, drug use disorders, cannabis use disorder, cocaine dependence, opioid use disorder, alcoholism, psychosis, hospital discharge data, propensity score matching, schizophrenia risk
- MeSH terms
- Adult, California, Female, Humans, Male, Methamphetamine, Middle Aged, Risk Factors, Schizophrenia, Schizophrenic Psychology, Cohort Studies, Diagnosis, Dual (Psychiatry), Amphetamine-Related Disorders
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.